Issue link: https://www.e-digitaleditions.com/i/1073928
Inhalation February 2019 21 generator and a pressurized metered dose inhaler. Int. J. Pharm. 198:63-70. 20. Gonda I, (1998) Mathematical modeling of deposition and disposition of drugs administered via the nose. Adv. Drug Deliv. Rev. 29:179-184. 21. FY2016 Regulatory Science Report: Local- ly-Acting Orally-Inhaled and Nasal Drug Products (2016), https://www.fda.gov/ForIndustry/UserFees/ GenericDrugUserFees/ucm549167.htm. (Accessed November 29, 2018). 22. Market Watch (2018) Nasal drug delivery tech- nology market is expected to exceed US$ 64 billion by 2023, https://www.marketwatch.com/press- release/nasal-drug-delivery-technology-market-is- expected-to-exceed-us-64-billion-by-2023-2018- 09-07. (Accessed November 29, 2018). 23. Usmani OS et al, (2005) Regional lung deposi- tion and bronchodilator response as a function of ß2-agonist particle size. Am. J. Respir. Crit. Care Med. 172:1497-1504. 24. Farr SJ et al, (1995) Aerosol deposition in the human lung following administration from a micro- processor controlled pressurised metered dose inhaler. orax. 50:639-644. Inhalation's editorial board member Jolyon Mitchell, PhD served as advisor for the development and review of this Point of View article. Igor Gonda, PhD is the Founder and CEO of Respidex, LLC, 650 Delancey Street, Suite 218, San Francisco, CA 94107, US, Tel.: +1 510 731-8820, igonda@ respidex.com. 4. Bugos GE, (2003) G.Kirk Raab, CEO at Genen- tech 1990-1995, http://digitalassets.lib.berkeley. edu/roho/ucb/text/RaabBook.pdf. (Accessed November 29, 2018). 5. Patient-Focused Drug Development: Disease Area Meetings Held in Fiscal Years 2013-2017 (2018), https://www.fda.gov/forindustry/userfees/prescrip tion d r uguser fee/ucm 347317.h tm . (Accessed November 29, 2018). 6. Polverino E et al, (2017) European Respiratory Society guidelines for the management of adult bronchiectasis. Eur. Respir. J. 50:pii1700629. 7. Paudel A et al, (2015) Raman spectroscopy in pharmaceutical product design. Adv. Drug Deliv. Rev. 89:3-20. 8. Bonam M et al, (2008) Minimizing variability of cascade impaction measurements in inhalers and nebulizers. AAPS PharmSciTechnol. 9(2):404-413. 9. Phipps PR and Gonda I, (1990) Droplets produced by medical nebulizers: Some factors affecting their size and solute concentration. Chest. 97:1327-1332. 10. Phipps PR and Gonda I, (1994) Evaporation of aqueous aerosols produced by jet nebulizers: Effects on particle size and concentration of solution in the droplets. J. Aerosol Med. 7:239-258. 11. Finlay WH and Stapleton KW, (1999) Undersiz- ing of droplets from a vented nebulizer caused by aerosol heating during transit through an Anderson impactor. J. Aerosol Sci. 30:105-109. 12. Kwong WTJ et al, (2000) Comparison of nebu- lized particle size distribution with Malvern laser diffraction analyzer versus Andersen cascade impac- tor and low-flow Marple personal cascade impactor. J. Aerosol Med. 13:304-314. 13. Mercer TT et al, (1968) Operating characteris- tics of some compressed-air nebulizers. Am. Ind. Hyg. Assoc. J. 29:66-78. 14. Clark AR, (1995) e use of laser diffraction for the evaluation of the aerosol clouds generated by medical nebulizers. Int. J. Pharm. 115:69-78. 15. Gonda I, (1988) Drugs administered directly into the respiratory tract: Modeling of the duration of effective drug levels. J. Pharm. Sci. 77: 340-346. 16. Grgic B et al, (2004) In vitro intersubject and intrasubject deposition measurements in realistic mouth-throat geometries. Aerosol Sci. 35:1025-1040. 17. Stahlhofen W et al, (1989) Intercomparison of experimental regional aerosol deposition data. J. Aerosol Med. 2:285-308. 18. Martin AR et al, (2018) Models of deposition, pharmacokinetics, and intersubject variability in respiratory drug delivery. Opinion on Drug Deliv- ery, DOI: 10.1080/17425247.2018.1544616. 19. Farr SF et al, (2000) Comparison of in vitro and in vivo efficiencies of a novel unit-dose liquid aerosol SubScribe today www.inhalationmag.com